Compare BIO-TECHNE Corp (TECH) vs Texas Instruments Incorporated (TXN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs Texas Instruments Incorporated — how do they compare? BIO-TECHNE Corp trades at $72.1 (market cap $11.24B), while Texas Instruments Incorporated trades at $281.19 (market cap $256.11B). The key difference: Texas Instruments Incorporated is far larger — about 22.8× BIO-TECHNE Corp's market cap, and Texas Instruments Incorporated pays the higher dividend (2.03%). Which is the better fit depends on your goals.
| TECH | TXN | |
|---|---|---|
Market Cap | $11.24B | $256.11B |
Sector | Health | Technology |
52-Week High | $72.29 | $332.35 |
52-Week Low | $43.31 | $153.33 |
Enterprise Value | $11.32B | $263.16B |
Dividend Yield | 0.44% | 2.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Texas Instruments (TXN) trades at $286.08, up 2.76% in the last 24 hours, with a bullish technical signal and strong earnings beats in recent quarters. The company shows robust profitability with a 31.11% net income margin and 34.97% ROE, though valuation ratios like P/E of 43.48 are elevated. Recent news highlights CFO transition and AI-driven demand growth, supporting positive sentiment.
Outlook remains favorable with a consensus price target of $333.10, but risks include high debt-to-asset ratio of 40.61% and competitive pressures. Investment opportunity lies in operational leverage from 300mm capacity expansion, while macroeconomic volatility and execution risks warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About Texas Instruments Incorporated
Dallas-based Texas Instruments generates over 95% of its revenue from semiconductors and the remainder from its well-known calculators. Texas Instruments is the world's largest maker of analog chips, which are used to process real-world signals such as sound and power. Texas Instruments also has a leading market share position in processors and microcontrollers used in a wide variety of electronics applications.
Read more on TXN →
